P.-J. Souquet

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial

Denis Moro‐Sibilot, Nathalie Cozic, M. Pérol et al. · Annals of Oncology · 2019 · 192 citations · Full text

Medicinal Chemistry, Ros1-positive Nsclc, Medicine +4

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations

Julien Mazières, Claire Cropet, Laure Montané et al. · Annals of Oncology · 2020 · 185 citations

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

Martin Reck, Tudor–Eliade Ciuleanu, Manuel Cobo et al. · ESMO Open · 2021 · 184 citations · Full text

Multicentre phase II study of cisplatin–etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study

J. Le Treut, M. C. Sault, H. Léna et al. · Annals of Oncology · 2013 · 173 citations · Full text

Medicine, Cisplatin–etoposide Chemotherapy, Pathology +8

Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin

Jean-Louis Pujol, Jean-Luc Breton, R. Gervais et al. · Annals of Oncology · 2005 · 129 citations

Gemcitabine–docetaxel Versus Cisplatin–vinorelbine, Medicine, Anti-cancer Agent +8